

Jonathan D Gill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1339513/publications.pdf>

Version: 2024-02-01

36
papers

1,827
citations

535685

17
h-index

425179

34
g-index

44
all docs

44
docs citations

44
times ranked

2553
citing authors

#	ARTICLE	IF	CITATIONS
1	Current and future therapeutic approaches for osteosarcoma. Expert Review of Anticancer Therapy, 2018, 18, 39-50.	1.1	539
2	Advancing therapy for osteosarcoma. Nature Reviews Clinical Oncology, 2021, 18, 609-624.	12.5	319
3	Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Scientific Reports, 2016, 6, 30093.	1.6	213
4	Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer, 2014, 120, 548-554.	2.0	130
5	HLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival. Scientific Reports, 2016, 6, 31154.	1.6	69
6	Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma. Clinical Sarcoma Research, 2015, 5, 4.	2.3	55
7	Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma. Pediatric Blood and Cancer, 2016, 63, 32-38.	0.8	46
8	Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma. Scientific Reports, 2018, 8, 14294.	1.6	45
9	Insulin-Like Growth Factor 1 Receptor and Response to Anti-IGF1R Antibody Therapy in Osteosarcoma. PLoS ONE, 2014, 9, e106249.	1.1	38
10	Detection of circulating tumor DNA in patients with osteosarcoma. Oncotarget, 2018, 9, 12695-12704.	0.8	38
11	Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R). Nuclear Medicine and Biology, 2016, 43, 812-817.	0.3	28
12	Genetically transforming human osteoblasts to sarcoma: development of an osteosarcoma model. Genes and Cancer, 2017, 8, 484-494.	0.6	26
13	A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin. Pediatric Blood and Cancer, 2018, 65, e27224.	0.8	24
14	HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study. Pediatric Blood and Cancer, 2014, 61, 1558-1564.	0.8	23
15	Challenges of Clinical Management of Adolescent and Young Adults With Bone and Soft Tissue Sarcoma. Cancer Journal (Sudbury, Mass), 2018, 24, 301-306.	1.0	20
16	Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patients. International Journal of Cancer, 2020, 147, 3550-3559.	2.3	19
17	Pediatric Oncology Provider Views on Performing a Biopsy of Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling. Annals of Surgical Oncology, 2016, 23, 990-997.	0.7	17
18	ABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium. Molecular Cancer Therapeutics, 2021, 20, 535-540.	1.9	17

#	ARTICLE	IF	CITATIONS
19	The effect of bone morphogenetic protein-2 on osteosarcoma metastasis. PLoS ONE, 2017, 12, e0173322.	1.1	17
20	Reconstruction of the Pediatric Midface Following Oncologic Resection. Journal of Reconstructive Microsurgery, 2015, 31, 336-342.	1.0	16
21	Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies. Cancer Medicine, 2016, 5, 294-303.	1.3	14
22	Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis: Impact of Family History. Journal of Pediatric Hematology/Oncology, 2018, 40, e359-e363.	0.3	13
23	Provider views on the management of Ewing sarcoma of the spine and pelvis. Journal of Surgical Oncology, 2018, 117, 417-424.	0.8	12
24	Survey of Paediatric Oncologists and Pathologists regarding Their Views and Experiences with Variant Translocations in Ewing and Ewing-Like Sarcoma: A Report of the Children's Oncology Group. Sarcoma, 2020, 2020, 1-9.	0.7	12
25	HER-2 Involvement in Osteosarcoma. Advances in Experimental Medicine and Biology, 2014, 804, 161-177.	0.8	12
26	Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma. Molecular Cancer Therapeutics, 2022, 21, 903-913.	1.9	12
27	Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium. Pediatric Blood and Cancer, 2020, 67, e28606.	0.8	9
28	Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium. Pediatric Blood and Cancer, 2020, 67, e28222.	0.8	8
29	Impact of Lagtime, Health Insurance Type, and Income Status at Diagnosis on the Long-Term Survival of Adolescent and Young Adult Cancer Patients. Journal of Adolescent and Young Adult Oncology, 2021, 10, 164-174.	0.7	8
30	HER2-Targeted Therapy in Osteosarcoma. Advances in Experimental Medicine and Biology, 2020, 1257, 55-66.	0.8	7
31	High-Dose Chemotherapy with Stem Cell Rescue in Desmoplastic Small Round Cell Tumor: A Single-Institution Experience and Review of the Literature. Sarcoma, 2018, 2018, 1-10.	0.7	6
32	Initial <i>in vivo</i> testing of TPO-receptor agonist eltrombopag in osteosarcoma patient-derived xenograft models by the pediatric preclinical testing consortium. Pediatric Hematology and Oncology, 2021, 38, 8-13.	0.3	6
33	Prognostic and Therapeutic Utility of Variably Expressed Cell Surface Receptors in Osteosarcoma. Sarcoma, 2021, 2021, 1-10.	0.7	6
34	Pediatric oncologist willingness to offer germline <i>TP53</i> testing in osteosarcoma. Cancer, 2018, 124, 1242-1250.	2.0	3
35	Inherited Hematologic and Oncologic Syndromes. Pediatrics in Review, 2011, 32, 401-404.	0.2	0
36	PATH-29. HIGH FREQUENCY OF CLINICALLY-RELEVANT TUMOR VARIANTS DETECTED BY MOLECULAR TESTING OF HIGH-RISK PEDIATRIC CNS TUMORS – PRELIMINARY FINDINGS FROM THE TEXAS KidsCanSeq STUDY. Neuro-Oncology, 2020, 22, iii430-iii430.	0.6	0